SCHEMBL6794058

SCHEMBL6794058

Clc1ccc2ccncc2c1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.50
IMPDH2 P12268 2/20 0.46
CLK1 P49759 1/20 0.43
DYRK1A Q13627 1/20 0.43
TNF P01375 1/20 0.40
GAA P10253 1/20 0.40
MAPK10 P53779 3/20 0.38
HIPK2 Q9H2X6 2/20 0.38
CYP17A1 P05093 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP11B1 P15538 2/20 0.37
CYP11B2 P19099 2/20 0.37
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
HTT P42858 1/20 0.36
RAD52 P43351 1/20 0.36
CYP19A1 P11511 2/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11737866 0.98 CYP2A6 (0.48) CYP2A6IMPDH2CLK1DYRK1ATNF
Iodomethane SCHEMBL11741710 0.94 CYP2A6 (0.45) CYP2A6IMPDH2CLK1DYRK1ATNF
SCHEMBL6804952 0.83 IMPDH2 (0.66) CYP2A6IMPDH2DYRK1AGAACYP3A4
SCHEMBL11736164 0.79 CLK1 (0.49) IMPDH2CLK1DYRK1ATNFGAA
SCHEMBL11179959 0.79 IMPDH2 (0.43) IMPDH2CLK1DYRK1ATNFGAA
SCHEMBL11478088 0.79 EP300 (0.44) IMPDH2CLK1DYRK1ATNFMAPK10
SCHEMBL30210705 0.79 CLK1 (0.49) IMPDH2CLK1DYRK1ATNFGAA
SCHEMBL11743241 0.79 CLK1 (0.41) CYP2A6IMPDH2CLK1DYRK1ATNF
SCHEMBL11744857 0.79 IMPDH2 (0.43) CYP2A6IMPDH2CLK1DYRK1ATNF
SCHEMBL27040501 0.79 IMPDH2 (0.43) CYP2A6IMPDH2CLK1DYRK1ATNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023044171-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. (US) 2023-03-23 WO disclosed
US-20040122223-A1 Non-natural nucleotides and dinucleotides CELLTECH R & D LIMITED (GB) 2004-06-24 US disclosed
EP-1368366-A1 NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES Celltech R & D Limited (GB) 2003-12-10 EP disclosed
WO-2002062816-A1 NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES CELLTECH R & D LIMITED (GB) 2002-08-15 WO disclosed
US-4228170-A INHIBITOR OF PHENYLETHANOLAMINE N-METHYLTRANSFERASE SMITHKLINE CORPORATION (US) 1980-10-14 US disclosed
US-4200754-A Method for preparing 7,8-dichloro-1,2,3,4-tetrahydroisoquinoline SMITHKLINE CORPORATION (US) 1980-04-29 US disclosed
US-4062961-A SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES SMITHKLINE CORPORATION (US) 1977-12-13 US disclosed
US-3988339-A 7 OR 8-SUBSTITUTED 1,2,3,4-TETRAHYDRO-ISOQUINOLINE SMITHKLINE CORPORATION (US) 1976-10-26 US disclosed
US-3939164-A PHENYLETHANOLAMINE N-METHYL TRANSFERASE INHIBITORS SMITHKLINE CORPORATION (US) 1976-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122223-A1 Non-natural nucleotides and dinucleotides P2RY1, P2RY11, P2RY13 CYP2A6 2553/4885IMPDH2 982/4885CLK1 3706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.